Form 8-K Arcus Biosciences, Inc. For: Jul 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Arcus Biosciences (RCUS) Chief Medical Officer Move to Gilead (GILD) Suggests Strengthened Relationship Between the Companies - Mizuho
July 20, 2021 6:47 AM EDTMizuho Securities analyst Mara Goldstein reiterated a Buy rating and $43.00 price target on Arcus Biosciences (NYSE: RCUS) after it was announced the transition of Chief Medical Officer - William "Bill" Grossman M.D., Ph.D. - to senior vice president of oncology at GILD overseeing... More
Arcus Biosciences (RCUS) Chief Medical Officer Grossman to Leave for Gilead (GILD)
July 19, 2021 5:10 PM EDTArcus Biosciences (NYSE: RCUS) announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (NASDAQ: GILD) as senior vice president of oncology clinical research to oversee Gileads clinical-stage oncology portfolio. This will include leading Gileads efforts in the companys alliance with Arcus to co-develop and co-commercialize... More
